DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Remicade (Infliximab) - Published Studies

 
 



Remicade Related Published Studies

Well-designed clinical trials related to Remicade (Infliximab)

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). [2014]

A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. [2013]

Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. [2013]

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). [2011.11]

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. [2011.09]

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. [2011.07]

Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. [2011.04]

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. [2011.03]

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. [2011.03]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2011.02]

Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. [2011.01]

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. [2011]

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. [2011]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2010.12.07]

Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. [2010.12]

Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. [2010.12]

Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. [2010.10]

Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. [2010.10]

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. [2010.10]

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. [2010.09.07]

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. [2010.09]

Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. [2010.08.01]

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. [2010.08]

Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. [2010.08]

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. [2010.07]

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. [2010.07]

A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. [2010.06]

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). [2010.05]

Infliximab, azathioprine, or combination therapy for Crohn's disease. [2010.04.15]

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. [2010.04]

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. [2010.04]

[Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis]. [2010.04]

Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. [2010.03]

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. [2010.02]

Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. [2010.02]

Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. [2010.02]

Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. [2010]

C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. [2010]

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. [2010]

Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. [2010]

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. [2010]

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. [2010]

A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. [2010]

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. [2010]

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). [2010]

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. [2009.12]

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. [2009.12]

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. [2009.12]

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. [2009.12]

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. [2009.10]

Cost-effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomized controled trial. [2009.09.09]

A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. [2009.09]

Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. [2009.08.15]

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. [2009.08.08]

Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. [2009.08]

Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. [2009.08]

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. [2009.08]

Infliximab improves vascular stiffness in patients with rheumatoid arthritis. [2009.08]

Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: A Belgian case series. [2009.07.27]

Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. [2009.07.15]

Efficacy and safety of infliximab in active SLE: a pilot study. [2009.07]

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. [2009.07]

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. [2009.06]

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. [2009.05.15]

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. [2009.04]

Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. [2009.03]

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. [2009.03]

Infliximab prevents Crohn's disease recurrence after ileal resection. [2009.02]

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. [2009.02]

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. [2009]

Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial. [2008.12.25]

Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. [2008.12]

Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. [2008.12]

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. [2008.10.15]

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. [2008.10]

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. [2008.09.15]

Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. [2008.09]

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. [2008.09]

Patterns of infliximab use among Crohn's disease patients in a community setting. [2008.09]

Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). [2008.08.22]

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2008.08]

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. [2008.06]

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. [2008.06]

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. [2008.06]

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). [2008.05]

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. [2008.05]

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. [2008.04]

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. [2008.03]

Efficacy of Infliximab in Extrapulmonary Sarcoidosis: Results from a Randomized Trial. [2008.02.06]

A review of infliximab use in ulcerative colitis. [2008.02]

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. [2008.02]

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. [2008.01]

Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2008.01]

Effect of infliximab on the levels of TNF-alpha and TGF-beta in the whole blood cultures of irradiated patients. [2008]

Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. [2008]

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. [2007.12.28]

Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2007.11.29]

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. [2007.10.08]

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. [2007.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014